Payment overview · 2025
General Payments
$962.82
40 reported records · 8 companies
Healthcare provider profile · identity verified
Anil S Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HEMPSTEAD, NY · NPI 1497739635
Verified facts
What the public records show
CMS Open Payments records show Anil S Patel, MD received $962.82 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $471.78 | 49.0% | 19 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $183.59 | 19.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.20 | 10.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.80 | 7.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.86 | 5.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.97 | 3.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.83 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.79 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $962.82 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $371.65 | 14 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $183.59 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.20 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.13 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.80 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.86 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.97 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 78 |
| Losartan Potassium | Losartan Potassium | 194 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 67 |
| Glimepiride | Glimepiride | 178 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 20 |
| Metformin Hcl Er | Metformin Hcl | 149 | 52 |
| Metformin Hcl | Metformin Hcl | 147 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 24 |
| Famotidine | Famotidine | 134 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 44 |
| Gabapentin | Gabapentin | 107 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 32 |
| Ozempic | Semaglutide | 95 | 16 |
| Lisinopril | Lisinopril | 92 | 29 |
| Simvastatin | Simvastatin | 82 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 74 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 29 |
| Atenolol | Atenolol | 66 | 19 |
| Azithromycin | Azithromycin | 62 | 50 |
| Carvedilol | Carvedilol | 62 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 20 |
| Montelukast Sodium | Montelukast Sodium | 58 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 19 |
| Nifedipine Er | Nifedipine | 55 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 53 | 18 |
| Clonazepam | Clonazepam | 52 | 18 |
| Meloxicam | Meloxicam | 49 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Eliquis | Apixaban | 47 | 15 |
| Linzess | Linaclotide | 47 | suppressed |
| Omeprazole | Omeprazole | 46 | 20 |
| Enalapril Maleate | Enalapril Maleate | 45 | 16 |
| Prednisone | Prednisone | 44 | 22 |
| Allopurinol | Allopurinol | 43 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Ammonium Lactate | Ammonium Lactate | 41 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | 13 |
| Furosemide | Furosemide | 39 | 14 |
| Spironolactone | Spironolactone | 39 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 12 |
| Azelastine Hcl | Azelastine Hcl | 29 | 23 |
| Finasteride | Finasteride | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 15 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Torsemide | Torsemide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $962.82 · 40 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, FARXIGA, GVOKE HYPOPEN, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error